Mycosis fungoides is a rare type of cancer in which certain white blood cells, called T lymphocytes, become malignant and attack the skin. Despite its name, it has nothing to do with a fungal infection. It is the most common form of cutaneous T-cell lymphoma, a group of cancers that start in the skin rather than in lymph nodes or bone marrow. The disease affects roughly 4.5 people per million each year, with an average age at diagnosis of 57.
Why It Starts in the Skin
T cells normally patrol the body looking for infections. A subset of them are specifically programmed to travel to the skin, guided by homing molecules on their surface. In mycosis fungoides, malignant T cells carry high levels of these skin-homing signals, particularly a molecule called CLA and a receptor called CCR4. These signals essentially lock the cancerous cells into a pattern of migrating to the skin and staying there, which is why the disease shows up as a skin condition long before it affects anything else. The malignant cells lack the molecular markers that would direct them to lymph nodes, which helps explain why mycosis fungoides tends to remain skin-confined for years or even decades.
Once in the skin, these rogue T cells also recruit normal immune cells into the area, creating the inflamed patches and plaques that define the disease’s appearance.
How It Looks and Progresses
Mycosis fungoides moves through a series of phases, though not everyone progresses through all of them. The earliest phase, sometimes called the premycotic phase, produces a scaly, red rash in areas that are typically covered by clothing and not exposed to the sun. This rash causes no symptoms and can persist for months or years. It looks so much like eczema or psoriasis that it is extremely difficult to diagnose at this point.
In the patch phase, the rash becomes a thin, reddened area resembling eczema. During the plaque phase, the skin develops raised, hardened lesions or small bumps that may be reddened. If the disease continues to advance, it enters the tumor phase, in which actual tumors form on the skin. These tumors can break open into ulcers and become infected.
Many people with mycosis fungoides remain in the patch or plaque phase for years without progressing further. A significant number never advance beyond early-stage disease.
Who Gets It
The disease is more common in men than women, and men tend to be diagnosed slightly later, at an average of about 59 years old compared to 55 for women. There are also racial differences: white patients are diagnosed at an average age of 59, while Black and Asian/Pacific Islander patients are diagnosed earlier, around age 51. The reasons for these demographic patterns are not fully understood.
How It Is Diagnosed
Diagnosing mycosis fungoides is notoriously difficult, especially in its early stages. The rash can mimic common skin conditions for years before a biopsy reveals what is really happening. A skin biopsy is the essential diagnostic tool, and pathologists look for specific hallmarks: malignant T cells with an unusual, convoluted shape, a band of abnormal cells clustered in the upper layer of the skin, and small collections of cancer cells within the outer skin layer known as Pautrier abscesses.
Multiple biopsies are often needed because early-stage disease may not show these classic features clearly. Additional testing for abnormal immune cell markers and evidence of a single expanding clone of T cells can strengthen the diagnosis. Even among experienced pathologists, agreeing on an early-stage diagnosis has historically been challenging, though standardized criteria have significantly improved consistency.
Staging and What It Means for Prognosis
Mycosis fungoides uses a specialized staging system that accounts for four factors: how much skin is involved, whether lymph nodes are affected, whether internal organs are involved, and whether malignant cells are circulating in the blood. This is called the TNMB system.
Skin involvement is categorized by severity. Stage T1 means patches or plaques covering less than 10% of the body’s surface area. T2 means 10% or more. T3 means one or more tumors at least 1 centimeter across. T4, the most extensive, means redness covering 80% or more of the body.
Prognosis varies dramatically by stage. A study of 525 patients found that those diagnosed at the earliest stage (IA) had a five-year survival rate of 96%, and their median survival was never reached during the study period, meaning most were still alive at last follow-up. Patients at stages IB or IIA had a five-year survival of 73%, with a median survival of about 13 years. For more advanced disease (stages IIB and III), five-year survival dropped to 44% with a median survival of four years. Stage IV disease carried a five-year survival of 27% and a median survival of roughly 1.5 years.
The key takeaway is that early-stage mycosis fungoides, which is how most people are diagnosed, carries a favorable long-term outlook.
How It Differs From Sézary Syndrome
Sézary syndrome is a closely related but distinct form of cutaneous T-cell lymphoma. While mycosis fungoides starts and largely stays in the skin, Sézary syndrome involves large numbers of malignant T cells circulating in the bloodstream from the outset. Patients with Sézary syndrome typically have widespread skin redness, severe itching, and enlarged lymph nodes. At a biological level, the malignant cells in Sézary syndrome behave like central memory T cells, carrying markers that direct them to both the skin and the lymph nodes. Mycosis fungoides cells, by contrast, act like effector memory T cells that are locked into skin residency. This biological difference helps explain why Sézary syndrome is more aggressive and systemic.
Treatment Approaches
Treatment depends heavily on the stage. Early-stage disease is usually managed with therapies directed at the skin itself. These include specialized UV light therapy (phototherapy), topical medications applied directly to affected areas, and localized radiation. The goal in early disease is to control symptoms and clear the skin, and many patients respond well enough to maintain a normal quality of life for years.
When the disease is more advanced or stops responding to skin-directed treatments, systemic therapies that work throughout the body become necessary. Options include medications that modify the immune response, treatments that target the cancer cells specifically, and in some cases, chemotherapy. One targeted treatment, a monoclonal antibody that locks onto the CCR4 receptor (the same homing molecule the cancer cells use to reach the skin), was approved by the FDA in 2018 for patients whose disease has returned or stopped responding after at least one prior systemic treatment. It received breakthrough therapy and orphan drug designations, reflecting both its importance for a rare disease and its clinical promise.
Because mycosis fungoides often progresses slowly, treatment decisions are typically made with a long time horizon in mind, balancing disease control against the side effects of more aggressive therapies.